PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/517,626
Filing Date	December 10, 2004
First Named Inventor	Gian Luca Araldi
Art Unit	~~Not Yet Assigned~~ 1626
Examiner Name	~~Not Yet Assigned~~ Jason Nolan
Attorney Docket Number	SNI-003US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JN	C1	WO 03/008377 A1	01-30-2003	Hoffmann La Roche		
JN	C2	EP 1 481 976 A1	12-01-2004	Ono Pharmaceutical Co., Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jason Nolan/	Date Considered	12/08/2006

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Gian Luca Araldi
Art Unit	~~N/A~~ 1626
Examiner Name	~~Not Yet Assigned~~ Jason Nolan
Attorney Docket Number	SNI-003US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JN	A1	3,873,566	03-25-1975	Scribner	
JN	A2	4,003,911	01-18-1977	Scribner	
JN	A3	4,033,989	07-05-1977	Bundy	
JN	A4	4,090,019	05-16-1978	Williams, *et al.*	
JN	A5	4,211,876	07-08-1980	Scribner	
JN	A6	5,605,814	02-25-1997	Abramovitz, *et al.*	
JN	A7	5,759,789	06-02-1998	Abramovitz, *et al.*	
JN	A8	6,211,197 B1	04-03-2001	Belley, *et al.*	
JN	A9	6,288,120 B1	09-11-2001	Cameron, *et al.*	
JN	A10	US2002/0065308 A1	05-30-2002	Cameron, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JN	A11	WO 96/03380 A1	02-08-1996	Zeneca Limited		
JN	A12	WO 96/06822 A1	03-07-1996	Zeneca Limited		
JN	A13	EP 0 752 421 A1	01-08-1997	Zeneca Limited		
JN	A14	WO 97/00863 A1	01-09-1997	Zeneca Limited		
JN	A15	WO 97/00864 A1	01-09-1997	Zeneca Limited		
JN	A16	EP 1 110 949 A1	06-27-2001	Pfizer Products Inc.		
JN	A17	WO 02/24647 A1	03-28-2002	Ono Pharmaceutical Co., Ltd.		
JN	A18	WO 03/007941 A1	01-30-2003	F.Hoffmann -La Roche AG		
JN	A19	WO 03/009872 A1	05-12 2004	Ono Pharmaceutical Co., Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JN	A20	Abramovitz, *et al.* "The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs." Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.	
JN	A21	Bennett, *et al.* "Synthesis and biological activity of a series of 1-aryl-3-pyrazolidinones." J Med Chem. 1976 May;19(5):715-7.	
JN	A22	Bole, *et al.* "Molecular cloning and characterization of the four rat prostaglandin E_2 prostanoid receptor subtypes." Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.	
JN	A23	Coleman, *et al.* "Prostanoids and their receptors. Comprehensive Medicinal Chemistry." 1990 3:643-714.	

Examiner Signature	/Jason Nolan/	Date Considered	12/08/2006

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2

Complete If Known	
Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Gian Luca Araldi
Art Unit	~~N/A.~~ 1626
Examiner Name	~~Not Yet Assigned~~ Jason Nolan
Attorney Docket Number	SNI-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JN	B1	Coleman, *et al.* "International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes." Pharmacol Rev. 1994 Jun;46(2):205-29.	
JN	B2	Corey, *et al.* "A stable and easily prepared catalyst for the enantioselective reduction of ketones. Applications to Multistep Systheses." J. Am. Chem. Soc. 1987. 109:7925-26.	
JN	B3	Fleisch, *et al.* "LY171883, 1-< 2-hydroxy-3-propyl-4-< 4-(1H-tetrazol-5-yl) butoxy > phenyl > ethanone, an orally active leukotriene D4 antagonist." J Pharmacol Exp Ther. 1985 Apr;233(1):148-57.	
JN	B4	Gardiner, PJ. "Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979." Br J Pharmacol. 1986 Jan;87(1):45-56.	
JN	B5	Hundertmark, *et al.* "$Pd(PhCN)_2Cl_2/P(t\text{-}Bu)_3$: a versatile catalyst for Sonogashira reactions of aryl bromides at room temperature." Org Lett. 2000 Jun 15;2(12):1729-31.	
JN	B6	Ichikawa, *et al.* "Molecular aspects of the structures and functions of the prostaglandin E receptors." J Lipid Mediat Cell Signal. 1996 Sep;14(1-3):83-7.	
JN	B7	Langlois, *et al.* "Intramolecular Mitsunobu reaction in the region- and stereoselective synthesis of cis-4,5-disubstituted piperidin-2-ones." Tetrahedron Letters. 2000 41:8285-8288.	
JN	B8	Macdonald, *et al.* "Syntheses of trans-5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles and trans-5-oxo-hexahydro-furo[3,2-b]pyrroles (pyrrolidine trans-lactams and trans-lactones): new pharmacophores for elastase inhibition." J Med Chem. 1998 Oct 8;41(21):3919-22.	
JN	B9	Mikolajczyk, *et al.* "Synthesi8s of (±)-Rosaprostol." J. Org. Chem. 1998. 63:8894-8897.	
JN	B10	Minami, *et al.* "Characterization of EP-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice." Br J Pharmacol. 1994 Jul;112(3):735-40.	
JN	B11	Nair, *et al.* "Folate analogues. 31. Synthesis of the reduced derivatives of 11-deazahomofolic acid, 10-methyl-11-deazahomofolic acid, and their evaluation as inhibitors of glycinamide ribonucleotide formyltransferase." J Med Chem. 1989 Jun;32(6):1277-83.	
JN	B12	Okuma, *et al.* "An Efficient Synthesis of (R)-(+)-Recifeiolide and Related Macrolides by Using Enantiomerically Pure (R)- (-)-5-Methyl-2,2,2-triphenyl-1,2A^5-oxaphospholane." Tetrahedron. 1998. 54:4243-50.	
JN	B13	Tani, *et al.* "Synthesis of a Highly Selective EP2-Receptor Agonist." Synlett. 2002, pp. 239-242.	
JN	B14	Thivierge, *et al.* "Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate." Blood. 1998 Jul 1;92(1):40-5.	
JN	B15	Ushikubi, *et al.* "Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors." Jpn J Pharmacol. 2000 Aug;83(4):279-85.	
JN	B16	Wilkinson, *et al.* "Diethylanilineborane: A Practical, safe, and consistent-quality borane source for the large-scale enantioselective reduction of a ketone intermediate in the synthesis of (R,R)-Formoterol." Organic Process Research & Development. 2002 6:146-8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jason Nolan/	Date Considered	12/08/2006